Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status
The designation enables sponsors to receive a paediatric priority review voucher.
Cytiva Navigating cell therapy WP 4
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
IASO Bio gains Hong Kong approval for Fucaso application
UK-developed leukaemia cell therapy to be offered on NHS
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
USPTO grants patent to Genprex’s Reqorsa gene therapy
FDA approves Sarepta’s updated Elevidys label for DMD
